SEARCH:   Advanced

Blood, 15 October 2008, Vol. 112, No. 8, pp. 3264-3273. Prepublished online as a Blood First Edition Paper on July 30, 2008; DOI 10.1182/blood-2008-05-155176. This Article Full Text Full Text (PDF) Supplemental Figures All Versions of this Article: blood-2008-05-155176v1 112/8/3264    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Google Scholar Articles by Caminschi, I. Articles by Lahoud, M. H. PubMed PubMed Citation Articles by Caminschi, I. Articles by Lahoud, M. H. Related Collections Immunobiology Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  IMMUNOBIOLOGY The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement Irina Caminschi1,*, Anna I. Proietto1,*, Fatma Ahmet1, Susie Kitsoulis1, Joo Shin Teh1, Jennifer C. Y. Lo1, Alexandra Rizzitelli2, Li Wu1, David Vremec1, Serani L. H. van Dommelen1, Ian K. Campbell1, Eugene Maraskovsky3, Hal Braley3, Gayle M. Davey1, Patricia Mottram4, Nicholas van de Velde4, Kent Jensen5, Andrew M. Lew1, Mark D. Wright6, William R. Heath1, Ken Shortman1, and Mireille H. Lahoud1 1 The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia; 2 Department of Biochemistry and Molecular Biology, Monash University, Melbourne, Australia; 3 CSL Limited, Melbourne, Australia; 4 Burnet Institute, Austin Hospital, Melbourne, Australia; 5 Human Immunology Laboratory, Schering-Plough Biopharma, Palo Alto, CA; and 6 Department of Immunology, Monash University, Melbourne, Australia A novel dendritic cell (DC)–restricted molecule, Clec9A, was identified by gene expression profiling of mouse DC subtypes. Based on sequence similarity, a human ortholog was identified. Clec9A encodes a type II membrane protein with a single extracellular C-type lectin domain. Both the mouse Clec9A and human CLEC9A were cloned and expressed, and monoclonal antibodies (mAbs) against each were generated. Surface staining revealed that Clec9A was selective for mouse DCs and was restricted to the CD8+ conventional DC and plasmacytoid DC subtypes. A subset of human blood DCs also expressed CLEC9A. A single injection of mice with a mAb against Clec9A, which targets antigens (Ags) to the DCs, produced a striking enhancement of antibody responses in the absence of added adjuvants or danger signals, even in mice lacking Toll-like receptor signaling pathways. Such targeting also enhanced CD4 and CD8 T-cell responses. Thus, Clec9A serves as a new marker to distinguish subtypes of both mouse and human DCs. Furthermore, targeting Ags to DCs with antibodies to Clec9A is a promising strategy to enhance the efficiency of vaccines, even in the absence of adjuvants. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020